BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16741368)

  • 1. Once daily sublingual immunotherapy without updosing--A new treatment schedule.
    Rodriguez F; Boquete M; Ibáñez MD; de la Torre-Martínez F; Tabar AI
    Int Arch Allergy Immunol; 2006; 140(4):321-6. PubMed ID: 16741368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
    Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
    Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial.
    Wang DH; Chen L; Cheng L; Li KN; Yuan H; Lu JH; Li H
    Laryngoscope; 2013 Jun; 123(6):1334-40. PubMed ID: 23616386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing.
    Moreno-Ancillo A; Moreno C; Ojeda P; Domínguez C; Barasona MJ; García-Cubillana A; Martín S
    J Investig Allergol Clin Immunol; 2007; 17(6):399-405. PubMed ID: 18088023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites.
    Passalacqua G; Pasquali M; Ariano R; Lombardi C; Giardini A; Baiardini I; Majani G; Falagiani P; Bruno M; Canonica GW
    Allergy; 2006 Jul; 61(7):849-54. PubMed ID: 16792583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
    Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
    Allergy; 2009 Jan; 64(1):179-86. PubMed ID: 19076534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
    Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens.
    Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF
    Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
    Kleine-Tebbe J; Ribel M; Herold DA
    Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy.
    Tonnel AB; Scherpereel A; Douay B; Mellin B; Leprince D; Goldstein N; Delecluse P; Andre C
    Allergy; 2004 May; 59(5):491-7. PubMed ID: 15080829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal immunotherapy in weed-induced allergic rhinitis.
    Gaglani B; Borish L; Bartelson BL; Buchmeier A; Keller L; Nelson HS
    Ann Allergy Asthma Immunol; 1997 Sep; 79(3):259-65. PubMed ID: 9305235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
    Esch RE; Bush RK; Peden D; Lockey RF
    Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
    Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
    J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
    TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
    Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
    Allergy; 2009 Sep; 64(9):1394-401. PubMed ID: 19764942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study.
    Sieber J; Neis M; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Merk H
    Expert Opin Drug Saf; 2012 Jan; 11(1):7-13. PubMed ID: 21980934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.